AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain ( 5.2% and 21.0% respectively) discontin...)

HOME >> MEDICINE >> TECHNOLOGY

AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain

5.2% and 21.0%, respectively) discontinued due to an adverse event than compared to placebo (11.4%). There were no statistically significant differences in serious adverse event rates with 7.6%, 4.8% and 4.1% reported in the DM/Q 45, DM/Q 30 and placebo groups, respectively, and no deaths occurred during the study.

For more details, a PDF version of each poster can be found at the Company's website (www.avanir.com).

About Diabetic Neuropathic Pain

Diabetic neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from diabetes. It is often described as burning, tingling, stabbing, or pins and needles in the feet, legs, hands or arms. An estimated 3.5 million people in the United States experience diabetic neuropathic pain according to the American Diabetes Association.

About Zenvia

Zenvia is a combination of two well-characterized compounds, the therapeutically active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. This first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways, through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity, and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of Involuntary Emotional Expression Disorder (IEED) and DPN pain.

In October 2006, the Company received an approvable letter for the treatment of Zenvia in IEED. To address safety concerns raised in the FDA's approvable letter for Zenvia for the treatment of IEED, the company intends to initiate a confirmatory Phase III study with a new lower quinidine dose formulation of Zenvia. In April 2007 AVANIR completed a Phase III study in patients with diabetic peripheral neuropathic pain where all primary endpoints were successfully met.
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

Post Your Comments:

(Date:12/17/2009)... RALEIGH, N.C., Dec. 17 Pharmaceutical Institute ... from GeneEd, Inc., a company specializing in life ... advanced e-courses, help expand Pharmaceutical Institute,s already extensive ... Institute is a leading provider of specialized training ... a subsidiary of Campbell Alliance. Financial terms ...

(Date:12/17/2009)... PHOENIX, Dec. 17 The Make-A-Wish Foundation ... million donation from the LATISSE ® ... sponsored by Allergan, Inc. ,, Based on the ... a wish come true, the campaign launched earlier ... the Make-A-Wish Foundation by leveraging the excitement around ...

(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq ... February 10, 2010 the U.S. Food and ... will review the New Drug Application (NDA) ... aggressive non-Hodgkin,s lymphoma (NHL). ODAC is an ... concerning the efficacy and safety of marketed ...

[0] Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc.[0] The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign [0] Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010

... at least 45% additional,reduction in patients' LDL-cholesterol ... May 17, 2007 /PRNewswire-FirstCall/ -- Isis,Pharmaceuticals, Inc. ... clinical trial of ISIS 301012 in patients ... which were,presented in March at the of ...

... 17, 2007 - BioLineRx Ltd. (TASE:,BLRX), Israel's ... containing data from its successfully completed,phase I ... GABA-enhanced,antipsychotic for the treatment of schizophrenia, have ... scientific,conferences. The data will be presented at ...

Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5 BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 2 BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 3

Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences

(Date:12/17/2009)... Helped, Healed, and Preserved Good Health , ... ... Association (IHRSA) announced today that as part of its Campaign for ... abilities to make 2010 the year we unite in a national ... daily exercise is highly valued and widely practiced. IHRSA is inviting ...

(Date:12/17/2009)... , , THURSDAY, Dec. 17 (HealthDay News) -- Among teenage ... least one of three common sexually transmitted infections -- ... becoming sexually active, a new study has found. , ... also found that it was common for these patients ... within four to six months after treatment of the ...

(Date:12/17/2009)... of Science in Human Resource Development Degree Online , ... ... -- Open enrollment has begun for Villanova’s newly online ... professionals whose busy schedules can’t accommodate a campus-based program. With ... online in March 2010, location is no longer a barrier ...

(Date:12/17/2009)... SAN DIEGO, Dec. 17 Neurocrine Biosciences, Inc. ... entered into a privately negotiated transaction to sell an ... to affiliates of Venrock at a price of $2.09 ... approximately $10 million. Neurocrine expects the financing to close ... closing conditions. ,, A shelf registration statement ...

(Date:12/17/2009)... Procedure Provides Efficient Mechanism to Pursue Approval ... Dec. 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... it has initiated the regulatory approval process ... under the Decentralized Procedure (DCP). The DCP ... company to simultaneously pursue regulatory approval for ...

Breaking Medicine News(10 mins):Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5 Health News:STDs Common Among Sexually Active Teen Girls in Cities 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3 Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2 Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3

[0] IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active [0] STDs Common Among Sexually Active Teen Girls in Cities [0] A World-Class HR Master's Degree Is Now Within Reach – 100% Online [0] Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million [0] Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe

... aspiring nurses about careers and online education. , ... ... the recent launch of their new website, online nursing degree ... their goal of connecting students with schools, Online Nursing Career also ...

... (Nasdaq: JAZZ ) announced today that the company ... November 11, 2008 at 2:50 p.m. EST, Dr. Samuel ... at the,Rodman & Renshaw 10th Annual Healthcare Conference in ... at 3:30 p.m. MST (5:30 p.m. EST), Dr.,Saks will ...

... of Zyvox and Cubicin is Driven Strongly ... a New Report from AMR and Decision,Resources, ... 4 Arlington,Medical Resources (AMR) and Decision Resources ... infections caused by methicillin-resistant Staphylococcus,aureus (MRSA), an ...

... Be Sold by A Uniquely-Trained Sales ... ... PSK) today announced that SANCUSO(R) (Granisetron Transdermal System),is now available by prescription ... was approved by,the U.S. Food and Drug Administration (F.D.A.) in September 2008 ...

... /PRNewswire-FirstCall/ Medizone International,Inc. (Pink Sheets: MZEI) announces ... TDV Global, Inc. (TDVGlobal.com). TDV Global,is a ... Approximately 70% of their business involves consulting ... private enterprise,mostly in the Health and Security ...

... rates far below goals, study finds , , TUESDAY, Nov. ... asthma and other high-risk illnesses are getting flu shots, ... from 1992 to 2002 for 18,703 adolescents with asthma, ... During the study period, vaccination rates improved, but only ...

Other Medicine News:Health News:Online Nursing Degree Seekers Gain a New Education Resource: OnlineNursingCareer.com 2 Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 2 Health News:Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections 3 Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2 Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3 Health News:Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc. 2 Health News:Too Many High-Risk Teens Not Getting Flu Shots 2

Online Nursing Degree Seekers Gain a New Education Resource: OnlineNursingCareer.com Jazz Pharmaceuticals to Present at Investor Conferences Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.Too Many High-Risk Teens Not Getting Flu Shots

Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....

Shandon Microscope Slide Cabinet with Drawers...

... is the first solid-state,photocoagulator to ... wavelengths. This advanced,laser system makes ... a red or green wavelength,during ... and ensures effective,patient results., For ...

... The PSL utilizes a high luminance white LED ... lightweight, compact design, to give you the freedom ... The PSL Slit Lamp weighs only about 1.5 ... easily and comfortably in your hand. Its ...

Medicine Products:

Shandon Modular Filing System Shandon Microscope Slide Cabinet with Drawers Integre Duo Red and Green Solid State Photocoagulator PSL Portable Slit Lamp

( 5.2% and 21.0% respectively) discontin...)AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain,Health